Bioforce Nanosciences Holdings (BFNH) Operating Expenses (2020 - 2026)

Bioforce Nanosciences Holdings has disclosed Operating Expenses across 7 years of filings, most recently posting $117733.0 for Q1 2026.

• Quarterly Operating Expenses fell 11.78% year-over-year to $117733.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $356429.0 (down 27.71% YoY) and the FY2024 annual result came in at $490437.0, up 3.92% from the prior year.
• Operating Expenses climbed to $117733.0 in Q1 2026, from $115915.0 in the prior quarter.
• Over five years, Operating Expenses peaked at $437011.0 in Q4 2022 and troughed at $113607.0 in Q3 2023.
• A 5-year average of $141254.1 and a median of $122305.5 in 2022 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses surged 262.06% — and 2023, when it tumbled 73.82%.
• Tracing BFNH's Operating Expenses over 5 years: stood at $437011.0 in 2022, then slumped by 73.82% to $114410.0 in 2023, then grew by 7.65% to $123160.0 in 2024, then declined by 5.88% to $115915.0 in 2025, then gained by 1.57% to $117733.0 in 2026.
• Business Quant data shows BFNH's Operating Expenses at $117733.0 in Q1 2026, $115915.0 in Q3 2025, and $122781.0 in Q2 2025.